Navigation Links
At Twelve Months Post-Launch, the Majority of Surveyed Oncologists Have Prescribed Xtandi to Their Docetaxel-Pretreated Metastatic Castrate-Resistant Prostate Cancer Patients
Date:12/9/2013

EXTON, Pa., Dec. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at 12 months following the U.S. launch of Medivation/Astellas Pharma's Xtandi for docetaxel-pretreated metastatic castrate-resistant prostate cancer (mCRPC), the majority of surveyed oncologists stated that they have prescribed Xtandi in clinical practice, whereas the majority of surveyed urologists indicated that they had not yet prescribed Xtandi. Of current non-prescribers who plan on prescribing Xtandi for docetaxel-pretreated mCRPC in the future, the majority of urologists and oncologists stated that they will prescribe Xtandi within the next six months.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The third wave of the LaunchTrends® Xtandi (US) report series—fielded 12 months following the launch of Xtandi for docetaxel-pretreated mCRPC in the United States—finds that surveyed physicians indicated that the lack of steroid requirement and the efficacy profile of Xtandi are among its top perceived advantages compared with Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga, a finding that is consistent with prior waves of research. Nearly one-quarter of surveyed physicians indicated that they perceive no disadvantage of Xtandi compared with Zytiga.

The report also finds that the majority of surveyed physicians stated that first-line use of Zytiga for the treatment of chemotherapy-naive mCRPC remains unchanged following the commercial availability of Xtandi in the docetaxel-pretreated mCRPC setting. According to surveyed oncologists, Zytiga is currently the first-line patient share leader for the treatment of chemotherapy-naive mCRPC and will remain so in six months' time.

"Up to half of surveyed physicians indicated that docetaxel-naive asymptomatic or minimally symptomatic mCRPC and docetaxel-naive symptomatic mCRPC are highly appropriate patient populations for Xtandi," said Decision Resources Group Senior Business Insights Analyst Khurram Nawaz, M.Sc. "If Xtandi is approved for the first-line, asymptomatic or minimally symptomatic mCRPC patient population, surveyed physicians stated that they would prescribe Xtandi to more than 40 percent of their patients in that setting."

LaunchTrends® Xtandi (US) is a three-wave syndicated report series designed to track the uptake of Xtandi following its launch for docetaxel-pretreated mCRPC at one month, six months and 12 months following Xtandi's commercial availability, based upon primary research with U.S. oncologists and urologists. LaunchTrends assess trial and use of new products, obstacles to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction. For this third wave of research, BioTrends surveyed 49 U.S. oncologists and 51 U.S. urologists, and conducted qualitative interviews with 10 U.S. oncologists and urologists in October 2013.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:
Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

 


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMDs MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
2. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
3. LDM Group and Polyglot Systems Partnership Brings Easy-to-Understand Medication Instructions to Over Twelve Languages
4. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
5. International Isotopes Inc. Announces Third Quarter And Nine Months 2013 Financial Results
6. Skyline Medical Announces Results for Third Quarter and First Nine Months of 2013
7. China Biologic Reports Financial Results for the Third Quarter and First Nine Months of 2013
8. Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
9. The Majority Of Oncologists Will Begin Using Biosimilar Monoclonal Antibodies Within 12 Months Of Launch
10. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
11. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
(Date:5/6/2017)... May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), ... 100,000 square feet to its Welch Allyn campus. ... commitment to bring more than 100 new jobs to ... Allyn has maintained a significant presence for more than ... new positions, a large portion of which will be ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... Leading CEOs from biotech, pharmaceutical, and ... 31st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/26/2017)... ... 26, 2017 , ... Somnoware, a leading provider of digital ... its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep device integration ... platform, initializing devices and importing studies are just one-click operations. This plugin streamlines ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... Peace Agreements being discussed by President Donald Trump and the rest of the world. ... speed up peace talks in the continuous battle between Israel and Palestine. The world’s ...
(Date:5/26/2017)... Francisco, CA (PRWEB) , ... May 26, 2017 , ... ... Francisco, is proud to announce a new, informational blog post on insurance options. If ... surgery, checking insurance plans may help save time and money. Visiting an in-network provider ...
Breaking Medicine News(10 mins):